Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma

The effectivenes of cancer vaccines in inducing CD8+Tcell responses remains a challenge, resulting in a need for testing more potent adjuvants. Our objective was to determine the safety and immunogenicity of vaccination against melanoma-related antigens employing MART-1, gp100, and tysosinase paptid...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Tarhini, Ahmad A, Leng, Siyang, Moschos, Stergios J, Yin, Yan, Sander, Cindy, Lin, Yan, Gooding, William E, Kirkwood, John M
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3483091/
https://ncbi.nlm.nih.gov/pubmed/22495394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e31825481fe
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi